John Vavricka

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

Affiliation history

Recorded current and former roles; source labels appear when available.

Recorded roles and earnings-call appearances connecting this person to public companies.

AVIR

Current role

2 calls Latest call 2026-03-05

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year	Company	Role	Salary	Bonus	Stock awards	Option awards	Incentive	Other	Total
2025	Atea Pharmaceuticals, Inc. (AVIR)	Chief Commercial Officer	$443,169	—	$292,842	$290,460	$177,268	$14,000	$1,217,738
2024	Atea Pharmaceuticals, Inc. (AVIR)	Chief Commercial Officer	$430,261	—	$398,112	$406,806	$137,684	$13,800	$1,386,663
2023	Atea Pharmaceuticals, Inc. (AVIR)	Chief Commercial Officer	$417,729	—	$463,000	$475,524	$146,205	$13,200	$1,515,658
2022	Atea Pharmaceuticals, Inc. (AVIR)	Chief Commercial Officer	$397,838	—	$249,900	$691,835	$171,070	$12,200	$1,522,843
2021	Atea Pharmaceuticals, Inc. (AVIR)	Chief Commercial Officer	$386,250	—	—	$6,070,896	$131,325	$10,944	$6,599,415

Earnings-call appearances and filed executive appointments or departures, newest first.